Samsung C&T invests $10 million in C2N Diagnostics to support advancements in Alzheimer's disease diagnostics and strengthen its position in the life sciences sector.
Information on the Target
Samsung C&T has announced an investment of $10 million in C2N Diagnostics, a company specializing in precise measurement and analysis of blood-based protein biomarkers. This investment is being made through a life sciences fund established in collaboration with its subsidiaries, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment.
C2N Diagnostics has developed innovative technology that enables the accurate diagnosis of Alzheimer's disease via blood testing. In addition to this groundbreaking diagnostic tool, the company is actively involved in clinical trials for Alzheimer's treatments and participates in various clinical studies related to central nervous system diseases globally, underscoring its technical strength in the industry.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biotechnology sector has been experiencing robust growth globally, with a particular emphasis on innovative diagnostic solutions in the United States. The demand for eff
Similar Deals
Marlin Equity Partners → Intelligent Locations
2025
Rittenhouse Ventures → S2N Health, Inc.
2025
Samsung
invested in
C2N Diagnostics
in 2025
in a Other VC deal
Disclosed details
Transaction Size: $10M